QLG1080 / Qilu Pharma - LARVOL DELTA

Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer (clinicaltrials.gov) - P3 | N=111 | Completed | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Jan 2026 | Trial primary completion date: Nov 2026 ➔ Jan 2026

Trial completion • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer (clinicaltrials.gov) - P3 | N=110 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P3 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor